Webinar Technology

The evolving landscape of epigenomics: Measuring and manipulating methylation

This webinar is brought to you by the Science/AAAS Custom Publishing Office

The evolving landscape of epigenomics: Measuring and manipulating methylation

09 May 2018

12:00 p.m. ET

Register now!

Speakers

Epigenomics offers insights into the complex, multilayered system of genome regulation. The decline in sequencing costs has enabled researchers to more aggressively pursue the regulatory mechanisms underlying human development and disease progression in cancer, neurodegenerative diseases, and other medical conditions. As these fields advance, there is an increasing need for standardized approaches to measuring and manipulating DNA methylation, while also managing experimental error and biases. To maintain data quality, it will be necessary to employ a robust system for detecting, measuring, and correcting experimental artifacts. Join our experts as they discuss the latest epigenetics tools, their applications, and the experimental challenges they’ve encountered.

During the webinar, the speakers will:

  • Introduce viewers to diverse approaches and tools for epigenetics research
  • Provide advice on uncovering experimental biases and artifacts that could negatively impact your data
  • Highlight resources and findings from the FDA Epigenomics Quality Control (EpiQC) group
  • Discuss the impact of DNA methylation on DNA replication
  • Answer your questions during the live broadcast!

This Webinar will last for approximately 60 minutes

Speaker bios

Alexander Meissner, Ph.D.

Max Planck Institute for Molecular Genetics
Berlin, Germany

Dr. Meissner is director of the Max Planck Institute for Molecular Genetics in Berlin, Germany, a visiting professor at Harvard University in the United States, and a visiting scholar at the Broad Institute of MIT and Harvard. Previously, he was a professor at Harvard University in the Harvard Department of Stem Cell and Regenerative Biology, and a faculty member of the Harvard Stem Cell Institute. He received his Ph.D. from Saarland University in Saarbrücken, Germany, completing part of his graduate work at the Whitehead Institute for Biomedical Research, at the Massachusetts Institute of Technology in Cambridge, Massachusetts, where he also undertook his postdoctoral training. Dr. Meissner received the GeneExpression Systems Epigenomics Young Innovator Award in 2009, and has frequently published his work in top international journals.

Christopher E. Mason, Ph.D.

Weill Cornell Medicine
New York, NY

Dr. Mason completed his B.S. at the University of Wisconsin–Madison, majoring in both genetics and biochemistry. He undertook his Ph.D. and postdoctoral training at Yale University before joining Weill Cornell Medicine in New York as an assistant professor. He is now an associate professor at Weill and director of its WorldQuant Initiative for Quantitative Prediction, as well as leader of the U.S. Food and Drug Administration’s SEQC2 Epigenomics Quality Control Working Group. His laboratory develops and deploys new biochemical and computational methods in functional genomics, to elucidate the genetic basis of human disease and human physiology, and to create and deploy novel techniques in next-generation sequencing and algorithms for tumor evolution, genome evolution, DNA and RNA modifications, and genome/epigenome engineering. His group also works with NASA to build integrated molecular portraits of genomes, epigenomes, transcriptomes, and metagenomes for astronauts, which help establish the molecular foundations and genetic defenses for enabling long-term human spaceflight. Dr. Mason was named as one of Popular Science’s “Brilliant Ten” scientists and has been featured as a TEDMED speaker. He has cofounded four biotechnology startup companies and serves as an advisor to many others.

Sean Sanders, Ph.D.

Science/AAAS
Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here